Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00049569 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2013-10-08

No results posted yet for this study

Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining more than one chemotherapy drug with imatinib mesylate may kill more cancer cells. Randomized phase II trial to study the effectiveness of combination chemotherapy and imatinib mesylate in treating children who have relapsed acute lymphoblastic leukemia.

Conditions

  • L1 Childhood Acute Lymphoblastic Leukemia
  • L2 Childhood Acute Lymphoblastic Leukemia
  • Non-T, Non-B Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • T-cell Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG

cytarabine

Given IT

DRUG

methotrexate

Given IT

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given PO

DRUG

pegaspargase

Given IM

DRUG

doxorubicin hydrochloride

Given IV

DRUG

imatinib mesylate

Given PO

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

BIOLOGICAL

filgrastim

Given SC

DRUG

leucovorin calcium

Given IV

DRUG

asparaginase

Given IM

DRUG

therapeutic hydrocortisone

Given IT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Elizabeth Raetz · Children's Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00049569 on ClinicalTrials.gov